Upcoming Webinar Series: Expand your HIV Toolkit with CA Statewide Trainings on Extended-Release Injectable Suspensions for HIV Treatment and Prevention (Starting January 20, 2022)

Purpose

The purpose of this four-part series is to equip California clinicians, pharmacists, and members of the healthcare team with an in-depth understanding of Cabotegravir/ Rilpivirine, the first FDA-approved long-acting injectable for patients with HIV. Attendees will gain real-world patient and provider perspectives; a guide to patient eligibility, clinical considerations, insurance coverage; and insight into cultural consideration. Participants will also have access to a comprehensive toolkit with FAQs, protocols, and other resources to strengthen confidence when implementing treatment.

Sessions and Learning Objectives

Register for Session 1: Medication Management 101: a foundation in prescribing practices, and clinic implementation experiences

• Interpret the available clinical trial data for injectable cabotegravir/rilpivirine 
• Explain logistical challenges for implementation of long acting injectables in a clinical practice setting 
• Describe potential solutions to address logistical challenges 
• Draw on current real-world experiences implementing and using injectable cabotegravir/rilpivirine 

Register for Session 2: Treatment in the Real World: join a patient-provider panel discussion and get answers to your own questions and FAQs

• Discuss patient, provider, healthcare administration experiences with cabotegravir/rilpivirine including cultural humility and medical mistrust 
• Identify organizational, clinic, and personnel needs to develop a long-acting injectable program 
• Discuss best practices for implementing long-acting injectable program, including the involvement of multidisciplinary roles 

Register for Session 3: Injectables for PrEP: foundations in clinical practices and lessons learned from other types of injectables for prevention

• Summarize the implementation considerations for long-acting injectables for PrEP 
• Utilize updated PrEP guidelines to apply evidence-based HIV prevention tools. 
• Apply shared decision making to support patient choices for PrEP medication choices. 
• Identify strategies to support consistent access to PrEP for patients. 

Register for Session 4: The Future of Injectables: discuss the possibilities now that prevention and care are possible

• Access a toolkit with checklists, protocols patient and provider FAQs 
• Review California ADAP and PrEP AP Coverage and Provider Reimbursement Mechanisms 
• Describe promising new injectables for HIV management and prevention in the FDA pipeline 
• Discuss local implementation strategies and practical applications for a range of clinical settings 

Register for all four sessions now!

Note: Registration to each webinar is highly encouraged as each event will cover different topics and build off one another.

Approved for 4 AAFP Prescribed credits.

This project is supported by the Health Resources and Services Administration(HRSA) of the U.S. Department of Health and Human Services(HHS)as part of an award totaling $3,278,366. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS or theU.S.Government.